On Monday, Shares of Warren Resources, Inc. (NASDAQ:WRES), lost -7.87% to $0.370.
Warren Resources, offered an update on the Company’s operations in its Marcellus, California, and Wyoming business units.
Warren continues to execute successfully on its five core business strategies: right sizing capital spending; optimizing current assets and protecting production against commodity risk; increasing liquidity; positioning for commodity price recovery; and pursuing selective growth opportunities.
Warren Resources, Inc., an independent energy company, engages in the exploration, development, and production of domestic onshore crude oil and gas reserves. The company primarily focuses on the exploration and development of waterflood oil recovery projects in the Wilmington field within the Los Angeles Basin of California; Marcellus Shale project in northeastern Pennsylvania; and coalbed methane natural gas properties located in the Rocky Mountain region.
Shares of Stanley Black & Decker, Inc. (NYSE:SWK), inclined 0.48% to $107.87, during its last trading session.
Stanley Black & Decker, will broadcast its second quarter 2015 earnings conference call on Thursday, July 30, 2015. The call will start at 8:00AM ET.
A news release outlining the financial results will be distributed before the market opens on Thursday, July 30, 2015.
Stanley Black & Decker, Inc. provides power and hand tools, mechanical access solutions, and electronic security and monitoring systems for various industrial applications.
At the end of Monday’s trade, Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), gained 0.03% to $149.13.
BioMarin Pharmaceutical, declared the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for drisapersen for the treatment of Duchenne Muscular Dystrophy amenable to exon 51 skipping. Validation of the MAA confirms that the submission is complete and starts the EMA’s standard review process. Day 120 questions will be received on 22 October 2015, leading to a potential CHMP opinion in the first half of 2016 and a European Commission Decision by the third quarter of 2016.
Drisapersen is an investigational antisense oligonucleotide drug candidate for the treatment of the largest subset of Duchenne muscular dystrophy (DMD) amenable to single exon skipping. Drisapersen induces the skipping of dystrophin exon 51, potentially providing a therapeutic benefit to DMD patients for whom skipping of exon 51 restores the proper dystrophin reading frame, corresponding to about 13% of DMD patients.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally.
Finally, Net Element International Inc (NASDAQ:NETE), ended its last trade with -11.68% loss, and closed at $0.220.
Net Element, declared signing by PayOnline of a new 3-year contract to process transactions for certain international dating networks, counting AnastasiaDate, AmoLatina and AsianDate.
The social networks receive over 150 million online visitors annually and have over 4 million registered users that spend over 360 million hours on the sites per year.
Net Element presently manages, operates and is in the process of integrating the PayOnline group of companies pending closing of Net Element’s acquisition of the company.
The contract with the majority owner of the dating networks, Social Discovery Ventures (“SDV”), provides for minimum net revenues to Net Element in the amount of $1.2 million over 3 years and a minimum transaction processing commitment of $300 million.
The contract underscores Net Element’s advantage as a global payments-as-a-service platform that facilitates cross-border transactions yet on-boards through a single interface.
Net Element, Inc., a global payments-as-a-service, operates as a technology provider with an integrated mobile and transactional services platform serving emerging market clients. The company, through its partner, TOT Group, Inc., operates Unified Payments that processes cashless transactions for card-present or card-not-present transactions, counting point-of-sale (POS), mobile POS (mPOS), EMV, near field communication, Apple Pay, Internet businesses, service-oriented businesses, and mail order/telephone order merchants, in addition to processes other cashless transactions, counting checks and direct debits.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
